User profiles for M Boeckh
 | Michael Boeckh, MDProfessor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center Verified email at fredhutch.org Cited by 56537 |
Quantitation of cytomegalovirus: methodologic aspects and clinical applications
… Michael Boeckh was supported in part by NIH grants CA 18029 and AI 41754-01. Guy Boivin
was supported in part by a grant (MA-13924) from the Medical Research Council of Canada…
was supported in part by a grant (MA-13924) from the Medical Research Council of Canada…
How we treat cytomegalovirus in hematopoietic cell transplant recipients
M Boeckh, P Ljungman - Blood, The Journal of the American …, 2009 - ashpublications.org
… High-dose acyclovir (500 mg/m 2 intravenously 3 times daily, followed by 800 mg 4 times
daily [adult dosing]) can reduce the risk of CMV infection and possibly CMV disease. The study …
daily [adult dosing]) can reduce the risk of CMV infection and possibly CMV disease. The study …
The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive …
M Boeckh, WG Nichols - Blood, 2004 - ashpublications.org
… Thus, both prophylaxis and preemptive therapy strategies have been extensively studied
(reviewed in Boeckh et al 1 ) and prevention protocols based on these strategies are now used …
(reviewed in Boeckh et al 1 ) and prevention protocols based on these strategies are now used …
Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity
M Boeckh, W Leisenring, SR Riddell… - Blood, The Journal …, 2003 - ashpublications.org
Ganciclovir effectively prevents cytomegalovirus (CMV) disease in the first 100 days after
allogeneic hematopoietic stem cell transplantation (HSCT), but late-onset CMV disease is …
allogeneic hematopoietic stem cell transplantation (HSCT), but late-onset CMV disease is …
Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized …
… AJOR ADVANCES have been made in the prevention M of cytomegalovirus (CMV) disease
… (PCR) in PBL8 and in plasma and ser ~ m . ~ ” ~ The CMV antigenemia assay detects CMV …
… (PCR) in PBL8 and in plasma and ser ~ m . ~ ” ~ The CMV antigenemia assay detects CMV …
[HTML][HTML] Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation
Background Toll-like receptors (TLRs) are essential components of the immune response to
fungal pathogens. We examined the role of TLR polymorphisms in conferring a risk of …
fungal pathogens. We examined the role of TLR polymorphisms in conferring a risk of …
[HTML][HTML] Cytomegalovirus: pathogen, paradigm, and puzzle
M Boeckh, AP Geballe - The Journal of clinical investigation, 2011 - Am Soc Clin Investig
… Image credits: antigenemia, pp65 + cell in a leukocyte cytospin preparation (M. Boeckh);
retinitis, ophthalmoscopic view of retinal hemorrhage and inflammation (E. Chuang); …
retinitis, ophthalmoscopic view of retinal hemorrhage and inflammation (E. Chuang); …
[HTML][HTML] Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective
M Tomblyn1, T Chiller2, H Einsele3, R Gress4, K Sepkowitz5, J Storek6, JR Wingard7, J-AH
Young8 and MJ Boeckh9
Young8 and MJ Boeckh9
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America
…, EJ Bow, KA Sepkowitz, MJ Boeckh… - Clinical infectious …, 2011 - academic.oup.com
This document updates and expands the initial Infectious Diseases Society of America (IDSA)
Fever and Neutropenia Guideline that was published in 1997 and first updated in 2002. It …
Fever and Neutropenia Guideline that was published in 1997 and first updated in 2002. It …
[HTML][HTML] Reduced mortality after allogeneic hematopoietic-cell transplantation
Background Over the past decade, advances have been made in the care of patients
undergoing transplantation. We conducted a study to determine whether these advances have …
undergoing transplantation. We conducted a study to determine whether these advances have …
